{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:08:33Z","timestamp":1793452113660,"version":"4.5.0"},"reference-count":206,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jacl.2026.01.011","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T07:45:14Z","timestamp":1769672714000},"page":"708-737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7810-4024","authenticated-orcid":false,"given":"Zahid","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandita","family":"Agarwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6808-3824","authenticated-orcid":false,"given":"Marina","family":"Cuchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Barton Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2861-5325","authenticated-orcid":false,"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hudgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8596-8351","authenticated-orcid":false,"given":"Allison","family":"Jamison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-4067","authenticated-orcid":false,"given":"Dinesh","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7255-6874","authenticated-orcid":false,"given":"Amit","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1922-7240","authenticated-orcid":false,"given":"Joshua W.","family":"Knowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iftikhar J","family":"Kullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3493-0895","authenticated-orcid":false,"given":"Ana","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Rothstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0341-5140","authenticated-orcid":false,"given":"Joseph J.","family":"Saseen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Soffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3635-7506","authenticated-orcid":false,"given":"Bruce A.","family":"Warden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7794-1835","authenticated-orcid":false,"given":"Lauren","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8876-099X","authenticated-orcid":false,"given":"Anne C.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.jacl.2026.01.011_bib1","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"issue":"10326","key":"10.1016\/j.jacl.2026.01.011_bib2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.011_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.atherosclerosis.2011.07.106","article-title":"Reduced penetrance of autosomal dominant hypercholesterolemia in a high percentage of families: importance of genetic testing in the entire family","volume":"218","author":"Garcia-Garcia","year":"2011","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib5","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/MOL.0b013e3283556c33","article-title":"Identification of people with heterozygous familial hypercholesterolemia","volume":"23","author":"Haase","year":"2012","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0002-9149(93)90155-6","article-title":"Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics","volume":"72","author":"Williams","year":"1993","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/aje\/kwh236","article-title":"Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review","volume":"160","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"6807","key":"10.1016\/j.jacl.2026.01.011_bib9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group","volume":"303","year":"1991","journal-title":"BMJ"},{"issue":"22","key":"10.1016\/j.jacl.2026.01.011_bib10","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib11","doi-asserted-by":"crossref","first-page":"558","DOI":"10.5551\/jat.CR005","article-title":"Guidelines for the diagnosis and treatment of adult familial hypercholesterolemia 2022","volume":"30","author":"Harada-Shiba","year":"2023","journal-title":"J Atheroscler Thromb"},{"issue":"24","key":"10.1016\/j.jacl.2026.01.011_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013225","article-title":"Diagnosis and treatment of heterozygous familial hypercholesterolemia","volume":"8","author":"McGowan","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib13","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jacl.2016.07.011","article-title":"US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry","volume":"10","author":"Ahmad","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jacl.2024.12.002","article-title":"Achilles tendon palpation for diagnosis of familial hypercholesterolemia: the compelling need to restore a valuable lost art","volume":"19","author":"Brinton","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2005.01484.x","article-title":"Pathogenesis, detection and treatment of Achilles tendon xanthomas","volume":"35","author":"Tsouli","year":"2005","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib16","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/j.jacl.2024.06.008","article-title":"Validation of physical examinations of tendon xanthomas and changes in the cutoff values of Achilles tendon thickness on radiography in the clinical criteria of heterozygous familial hypercholesterolemia in Japan","volume":"18","author":"Tada","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1399-0004.1998.tb03770.x","article-title":"Corneal arcus, case finding and definition of individual clinical risk in heterozygous familial hypercholesterolaemia","volume":"54","author":"Winder","year":"1998","journal-title":"Clin Genet"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.atherosclerosis.2006.08.060","article-title":"Corneal arcus as coronary artery disease risk factor","volume":"193","author":"Fern\u00e1ndez","year":"2007","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jacl.2022.04.001","article-title":"Applying an LDL-C threshold-based approach to identify individuals with familial hypercholesterolemia","volume":"16","author":"Jasani","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib20","first-page":"1457","article-title":"Simulation model to estimate pretreatment (baseline) low-density lipoprotein cholesterol levels in people living with homozygous familial hypercholesterolemia","volume":"19","author":"Gu","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib21","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jacl.2020.04.011","article-title":"Genetic testing in dyslipidemia: a scientific statement from the National Lipid Association","volume":"14","author":"Brown","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.01.011_bib22","doi-asserted-by":"crossref","first-page":"a1095","DOI":"10.1136\/bmj.a1095","article-title":"Familial hypercholesterolaemia: summary of NICE guidance","volume":"337","author":"Wierzbicki","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.011_bib24","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3390\/healthcare3030830","article-title":"Genomics in public health: perspective from the Office of Public Health Genomics at the Centers for Disease Control and Prevention (CDC)","volume":"3","author":"Green","year":"2015","journal-title":"Healthcare"},{"issue":"25","key":"10.1016\/j.jacl.2026.01.011_bib25","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The complex molecular genetics of familial hypercholesterolaemia","volume":"16","author":"Berberich","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"10.1016\/j.jacl.2026.01.011_bib27","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","article-title":"International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia","volume":"20","author":"Watts","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.gim.2021.09.012","article-title":"The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification","volume":"24","author":"Chora","year":"2022","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S2213-8587(19)30264-5","article-title":"Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement","volume":"8","author":"Hegele","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043224","article-title":"Genetic heterogeneity of familial hypercholesterolemia: repercussions for molecular diagnosis","volume":"24","author":"Di Taranto","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacl.2026.01.011_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.554931","article-title":"Genetics of hypercholesterolemia: comparison between familial hypercholesterolemia and hypercholesterolemia nonrelated to LDL receptor","volume":"11","author":"Jarauta","year":"2020","journal-title":"Front Genet"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib32","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2013.09.007","article-title":"APOE p.Leu167del mutation in familial hypercholesterolemia","volume":"231","author":"Awan","year":"2013","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib33","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.jacl.2025.09.016","article-title":"APOE p.(Leu167del) variant in hypercholesterolemia: prevalence & phenotypic expression","volume":"19","author":"Bello-\u00c1lvarez","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.01.011_bib34","series-title":"GeneReviews\u00ae","article-title":"Sitosterolemia","author":"Myrie","year":"2025"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.011_bib35","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.121.003390","article-title":"Screening of ABCG5 and ABCG8 genes for sitosterolemia in a familial hypercholesterolemia cascade screening program","volume":"15","author":"Tada","year":"2022","journal-title":"Circ Genom Precis Med"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib36","article-title":"Two cases of sitosterolemia falsely diagnosed as familial hypercholesterolemia: could digging deeper have avoided harm?","volume":"2","author":"Guay","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jacl.2016.11.002","article-title":"Lysosomal acid lipase deficiency: a hidden disease among cohorts of familial hypercholesterolemia?","volume":"11","author":"Chora","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/MOL.0000000000000740","article-title":"Update on cerebrotendinous xanthomatosis","volume":"32","author":"DeBarber","year":"2021","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.011_bib39","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/j.jacl.2024.03.004","article-title":"Genetically and clinically confirmed atypical cerebrotendinous xanthomatosis with normal cholestanol and marked elevations of bile acid precursors and bile alcohols","volume":"18","author":"DeBarber","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib40","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10545-017-0093-8","article-title":"Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX)","volume":"40","author":"Salen","year":"2017","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jacl.2022.10.011","article-title":"Severe hypercholesterolemia in a patient with very low albumin and normal renal function","volume":"17","author":"Varughese","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.jacl.2026.01.011_bib42","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1161\/ATVBAHA.116.308027","article-title":"Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically","volume":"36","author":"Wang","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib43","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1161\/CIRCGENETICS.112.963587","article-title":"Low prevalence of mutations in known loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort","volume":"5","author":"Ahmad","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11883-022-01018-6","article-title":"Monogenic versus polygenic forms of hypercholesterolemia and cardiovascular risk: are there any differences?","volume":"24","author":"Jacob","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2026.01.011_bib45","article-title":"The functional landscape of coding variation in the familial hypercholesterolemia gene LDLR","author":"Tabet","year":"2025","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/MOL.0000000000000925","article-title":"Genetic testing for familial hypercholesterolemia","volume":"35","author":"Zhang","year":"2024","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.011_bib47","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41436-018-0093-6","article-title":"Developing a conceptual, reproducible, rubric-based approach to consent and result disclosure for genetic testing by clinicians with minimal genetics background","volume":"21","author":"Ormond","year":"2019","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13073-021-00887-x","article-title":"Application of a framework to guide genetic testing communication across clinical indications","volume":"13","author":"Hallquist","year":"2021","journal-title":"Genome Med"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib49","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/jgc4.1643","article-title":"A descriptive investigation of clinical practice models used by cardiovascular genetic counselors in North America","volume":"32","author":"Rickman","year":"2023","journal-title":"J Genet Couns"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib50","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10897-017-0175-7","article-title":"Clinical cardiovascular genetic counselors take a leading role in team-based variant classification","volume":"27","author":"Reuter","year":"2018","journal-title":"J Genet Couns"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacl.2022.12.006","article-title":"Counseling couples at risk of having a child with homozygous familial hypercholesterolemia\u2014clinical experience and recommendations","volume":"17","author":"Tromp","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib52","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/jgc4.1194","article-title":"Genetic testing preferences and intentions in patients with clinically diagnosed familial hypercholesterolemia","volume":"29","author":"Wand","year":"2020","journal-title":"J Genet Couns"},{"key":"10.1016\/j.jacl.2026.01.011_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1161029","article-title":"Evolving cardiovascular genetic counseling needs in the era of precision medicine","volume":"10","author":"Morales","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"10.1016\/j.jacl.2026.01.011_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14080841","article-title":"Innovative implementation strategies for familial hypercholesterolemia cascade testing: the impact of genetic counseling","volume":"14","author":"Morgan","year":"2024","journal-title":"J Pers Med"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib55","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jacl.2023.08.007","article-title":"Impact of providing genetics-based future cardiovascular risk on LDL-C in patients with familial hypercholesterolemia","volume":"17","author":"Nomura","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib56","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00125817-200109000-00005","article-title":"What is genetic discrimination, and when and how can it be prevented?","volume":"3","author":"Rothstein","year":"2001","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib57","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/hast.1204","article-title":"Can genetic nondiscrimination laws save lives?","volume":"51","author":"Rothstein","year":"2021","journal-title":"Hastings Cent Rep"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib58","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMp1404776","article-title":"GINA, genetic discrimination, and genomic medicine","volume":"372","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacl.2026.01.011_bib59","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMp2024123","article-title":"Banning genetic discrimination in life insurance\u2014time to follow Florida's lead","volume":"383","author":"Rothstein","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.01.011_bib60","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev-genom-111119-011436","article-title":"Looking beyond GINA: policy approaches to address genetic discrimination","volume":"21","author":"Joly","year":"2020","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib61","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1210\/clinem\/dgab873","article-title":"Improving familial hypercholesterolemia diagnosis using an EMR-based hybrid diagnostic model","volume":"107","author":"Eid","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"10.1016\/j.jacl.2026.01.011_bib62","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1136\/heartjnl-2021-319742","article-title":"Case-finding and genetic testing for familial hypercholesterolaemia in primary care","volume":"107","author":"Qureshi","year":"2021","journal-title":"Heart"},{"issue":"8","key":"10.1016\/j.jacl.2026.01.011_bib63","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2589-7500(19)30150-5","article-title":"Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data","volume":"1","author":"Myers","year":"2019","journal-title":"Lancet Digit Health"},{"issue":"suppl 1","key":"10.1016\/j.jacl.2026.01.011_bib64","doi-asserted-by":"crossref","DOI":"10.3399\/bjgp24X738141","article-title":"Advancing familial hypercholesterolaemia (FH) screening in primary care: an updated systematic review of systematic screening methods for identificaton of FH","volume":"74","author":"Ayoub","year":"2024","journal-title":"Br J Gen Pract"},{"issue":"10","key":"10.1016\/j.jacl.2026.01.011_bib65","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/jamia\/ocaf140","article-title":"Electronic health records-based algorithms to screen for U.S. Centers for Disease Control and Prevention tier 1 genetic diseases: a scoping review","volume":"32","author":"Harris","year":"2025","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.jacl.2026.01.011_bib66","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2020.07.022","article-title":"Electronic health records to facilitate continuous detection of familial hypercholesterolemia","volume":"310","author":"Pepplinkhuizen","year":"2020","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib67","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jacl.2016.08.001","article-title":"Rapid identification of familial hypercholesterolemia from electronic health records: the SEARCH study","volume":"10","author":"Safarova","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"7","key":"10.1016\/j.jacl.2026.01.011_bib68","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamacardio.2019.1518","article-title":"Identifying familial hypercholesterolemia using a blood donor screening program with more than 1 million volunteer donors","volume":"4","author":"Jackson","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"suppl 5","key":"10.1016\/j.jacl.2026.01.011_bib69","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report","volume":"128","author":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents","year":"2011","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.jacl.2026.01.011_bib70","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21724","article-title":"Pediatric lipid screening prevalence using nationwide electronic medical records","volume":"7","author":"Thompson-Paul","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.011_bib71","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/j.jacl.2024.02.008","article-title":"Overcoming the real and imagined barriers to cholesterol screening in pediatrics","volume":"18","author":"Schubert","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.01.011_bib72","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jpeds.2016.12.078","article-title":"Cholesterol screening and treatment practices and preferences: a survey of United States Pediatricians","volume":"185","author":"de Ferranti","year":"2017","journal-title":"J Pediatr"},{"issue":"14","key":"10.1016\/j.jacl.2026.01.011_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10143090","article-title":"Cascade screening and treatment initiation in young adults with heterozygous familial hypercholesterolemia","volume":"10","author":"Peterson","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacl.2026.01.011_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2024.113973","article-title":"Comparison of clinical decision support tools to improve pediatric lipid screening","volume":"269","author":"Goren","year":"2024","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib75","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/jama.2017.8543","article-title":"Cascade screening for familial hypercholesterolemia and the use of genetic testing","volume":"318","author":"Knowles","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2026.01.011_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2021.100245","article-title":"Cost-effectiveness of cascade genetic testing for familial hypercholesterolemia in the United States: a simulation analysis","volume":"8","author":"Jackson","year":"2021","journal-title":"Am J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib77","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1055\/s-2004-822987","article-title":"Advanced method for the identification of patients with inherited hypercholesterolemia","volume":"4","author":"Defesche","year":"2004","journal-title":"Semin Vasc Med"},{"issue":"45","key":"10.1016\/j.jacl.2026.01.011_bib78","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.jacl.2026.01.011_bib79","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib80","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1377\/hlthaff.2017.1630","article-title":"Delivery of cascade screening for hereditary conditions: a scoping review of the literature","volume":"37","author":"Roberts","year":"2018","journal-title":"Health Aff"},{"issue":"9","key":"10.1016\/j.jacl.2026.01.011_bib81","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/s41436-021-01192-z","article-title":"A randomized controlled trial of genetic testing and cascade screening in familial hypercholesterolemia","volume":"23","author":"Ajufo","year":"2021","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib82","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.120.003120","article-title":"Developing and optimizing innovative tools to address familial hypercholesterolemia underdiagnosis: identification methods, patient activation, and cascade testing for familial hypercholesterolemia","volume":"14","author":"Campbell-Salome","year":"2021","journal-title":"Circ Genom Precis Med"},{"issue":"12","key":"10.1016\/j.jacl.2026.01.011_bib83","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.gim.2022.08.026","article-title":"A pragmatic clinical trial of cascade testing for familial hypercholesterolemia","volume":"24","author":"Miller","year":"2022","journal-title":"Genet Med"},{"issue":"9251","key":"10.1016\/j.jacl.2026.01.011_bib84","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(00)03587-X","article-title":"Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands","volume":"357","author":"Umans-Eckenhausen","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib85","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.ejhg.5201360","article-title":"Cascade testing in familial hypercholesterolaemia: how should family members be contacted?","volume":"13","author":"Newson","year":"2005","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib86","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/CIRCRESAHA.117.312319","article-title":"Lessening the burden of familial hypercholesterolemia using health information technology","volume":"122","author":"Safarova","year":"2018","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib87","doi-asserted-by":"crossref","DOI":"10.1093\/jlb\/lsaa071","article-title":"What guidance does HIPAA offer to providers considering familial risk notification and cascade genetic testing?","volume":"7","author":"Henrikson","year":"2020","journal-title":"J Law Biosci"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib88","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/jgc4.1266","article-title":"Perspectives from individuals with familial hypercholesterolemia on direct contact in cascade screening","volume":"29","author":"Schwiter","year":"2020","journal-title":"J Genet Couns"},{"key":"10.1016\/j.jacl.2026.01.011_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2021.100170","article-title":"A proof-of-concept study of cascade screening for familial hypercholesterolemia in the US, adapted from the Dutch model","volume":"6","author":"McGowan","year":"2021","journal-title":"Am J Prev Cardiol"},{"issue":"11","key":"10.1016\/j.jacl.2026.01.011_bib90","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.119.002723","article-title":"New case detection by cascade testing in familial hypercholesterolemia: a systematic review of the literature","volume":"12","author":"Lee","year":"2019","journal-title":"Circ Genom Precis Med"},{"issue":"25","key":"10.1016\/j.jacl.2026.01.011_bib91","doi-asserted-by":"crossref","first-page":"e1162","DOI":"10.1161\/CIR.0000000000000638","article-title":"Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology","volume":"139","author":"Lloyd-Jones","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib92","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.039454","article-title":"Evaluation and comparison of the PREVENT and pooled cohort equations for 10-year atherosclerotic cardiovascular risk prediction","volume":"14","author":"Zhou","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2026.01.011_bib93","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.atherosclerosis.2022.07.011","article-title":"Assessing the external validity of the SAFEHEART risk prediction model in patients with familial hypercholesterolaemia in an English routine care cohort","volume":"358","author":"McKay","year":"2022","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib94","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/MOL.0000000000000553","article-title":"Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all?","volume":"29","author":"Mata","year":"2018","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib95","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11547-023-01610-z","article-title":"Effectiveness of clinical scores in predicting coronary artery disease in familial hypercholesterolemia: a coronary computed tomography angiography study","volume":"128","author":"Catapano","year":"2023","journal-title":"Radiol Med"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib96","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/ATVBAHA.123.319957","article-title":"Increased FH-risk-score and diabetes are cardiovascular risk equivalents in heterozygous familial hypercholesterolemia","volume":"44","author":"Paquette","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2026.01.011_bib97","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2020.06.011","article-title":"SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia","volume":"306","author":"Gallo","year":"2020","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.jacl.2026.01.011_bib98","first-page":"2244","article-title":"Canadian and French risk scores are valid in identifying cardiovascular disease in Australian patients with familial hypercholesterolemia","volume":"41","author":"Tamehri Zadeh","year":"2025","journal-title":"Can J Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2026.01.011_bib99","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1161\/ATVBAHA.121.316106","article-title":"Familial hypercholesterolemia-risk-score: a new score predicting cardiovascular events and cardiovascular mortality in familial hypercholesterolemia","volume":"41","author":"Paquette","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"22","key":"10.1016\/j.jacl.2026.01.011_bib100","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study)","volume":"135","author":"P\u00e9rez de Isla","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib101","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jcmg.2019.11.001","article-title":"Absence of coronary artery calcification in middle-aged familial hypercholesterolemia patients without atherosclerotic cardiovascular disease","volume":"13","author":"Mszar","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib102","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cjco.2020.09.010","article-title":"Correlates of coronary artery calcification prevalence and severity in patients with heterozygous familial hypercholesterolemia","volume":"3","author":"Drouin-Chartier","year":"2021","journal-title":"CJC Open"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.011_bib103","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead046","article-title":"Coronary artery calcium among patients with heterozygous familial hypercholesterolaemia","volume":"3","author":"Tada","year":"2023","journal-title":"Eur Heart J Open"},{"issue":"12","key":"10.1016\/j.jacl.2026.01.011_bib104","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.jcmg.2021.06.011","article-title":"The added value of coronary calcium score in predicting cardiovascular events in familial hypercholesterolemia","volume":"14","author":"Gallo","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"9","key":"10.1016\/j.jacl.2026.01.011_bib105","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.jcmg.2018.09.019","article-title":"Coronary artery calcium and cardiovascular events in patients with familial hypercholesterolemia receiving standard lipid-lowering therapy","volume":"12","author":"Miname","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"14","key":"10.1016\/j.jacl.2026.01.011_bib106","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2026.01.011_bib107","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jcmg.2018.04.015","article-title":"Effects of statins on coronary atherosclerotic plaques: the PARADIGM study","volume":"11","author":"Lee","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib108","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/ATVBAHA.113.302074","article-title":"Role of computed tomography for diagnosis and risk stratification of patients with suspected or known coronary artery disease","volume":"34","author":"Kalra","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"10.1016\/j.jacl.2026.01.011_bib109","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/hrt.2010.220699","article-title":"CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia","volume":"97","author":"Neefjes","year":"2011","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib110","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.atherosclerosis.2010.10.001","article-title":"Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia","volume":"213","author":"Miname","year":"2010","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib111","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.amjcard.2014.12.034","article-title":"Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography","volume":"115","author":"Tada","year":"2015","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib112","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.atherosclerosis.2011.09.052","article-title":"Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia","volume":"219","author":"Neefjes","year":"2011","journal-title":"Atherosclerosis"},{"issue":"19","key":"10.1016\/j.jacl.2026.01.011_bib113","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.122.062557","article-title":"Alirocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia: the ARCHITECT study","volume":"147","author":"P\u00e9rez de Isla","year":"2023","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib114","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacl.2018.04.003","article-title":"Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study","volume":"12","author":"P\u00e9rez de Isla","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.01.011_bib115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2021.04.014","article-title":"Marked plaque regression in homozygous familial hypercholesterolemia","volume":"327","author":"Reeskamp","year":"2021","journal-title":"Atherosclerosis"},{"issue":"18","key":"10.1016\/j.jacl.2026.01.011_bib116","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib117","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jacl.2026.01.011_bib118","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-Year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.011_bib119","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jama.2023.8867","article-title":"Screening for lipid disorders in children and adolescents: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"330","author":"Guirguis-Blake","year":"2023","journal-title":"JAMA"},{"issue":"42","key":"10.1016\/j.jacl.2026.01.011_bib120","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.011_bib121","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/j.jacl.2024.01.006","article-title":"Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: consensus statement IV","volume":"18","author":"Puri","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"10106","key":"10.1016\/j.jacl.2026.01.011_bib122","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.jacl.2026.01.011_bib123","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1161\/CIRCULATIONAHA.116.024604","article-title":"Reductions in atherogenic lipids and major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing alirocumab with control","volume":"134","author":"Ray","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.01.011_bib124","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2019.08.007","article-title":"Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: the CASCADE FH registry","volume":"289","author":"Duell","year":"2019","journal-title":"Atherosclerosis"},{"issue":"13","key":"10.1016\/j.jacl.2026.01.011_bib125","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1161\/CIR.0000000000000618","article-title":"Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association","volume":"139","author":"de Ferranti","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib126","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacl.2022.07.011","article-title":"Nutrition interventions for youth with dyslipidemia: a National Lipid Association clinical perspective","volume":"16","author":"Williams","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib127","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jacl.2023.05.099","article-title":"Nutrition interventions for adults with dyslipidemia: a clinical perspective from the National Lipid Association","volume":"17","author":"Kirkpatrick","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"9","key":"10.1016\/j.jacl.2026.01.011_bib128","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jand.2023.05.015","article-title":"Healthy Eating Index-2020: review and update process to reflect the dietary guidelines for Americans,\u00a02020-2025","volume":"123","author":"Shams-White","year":"2023","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.jacl.2026.01.011_bib129","unstructured":"Dietary Guidelines for Americans, 2020\u20132025. 9th ed.; Services, U. S. D. o. A. a. U. S. D. o. H. a. H., Ed.; 2020. https:\/\/www.dietaryguidelines.gov\/sites\/default\/files\/2020-12\/DGA_2020-2025_ExecutiveSummary_English.pdf. Accessed Feb 13, 2026."},{"issue":"11","key":"10.1016\/j.jacl.2026.01.011_bib130","first-page":"e563","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.jacl.2026.01.011_bib131","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/jama.2018.14854","article-title":"The physical activity guidelines for Americans","volume":"320","author":"Piercy","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib132","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jand.2013.11.001","article-title":"Position of the academy of nutrition and dietetics: dietary fatty acids for healthy adults","volume":"114","author":"Vannice","year":"2014","journal-title":"J Acad Nutr Diet"},{"issue":"23","key":"10.1016\/j.jacl.2026.01.011_bib133","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1161\/CIR.0000000000001031","article-title":"2021 Dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association","volume":"144","author":"Lichtenstein","year":"2021","journal-title":"Circulation"},{"issue":"34","key":"10.1016\/j.jacl.2026.01.011_bib134","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.01.011_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106370","article-title":"Red yeast rice for dyslipidaemias and cardiovascular risk reduction: a position paper of the International Lipid Expert Panel","volume":"183","author":"Banach","year":"2022","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib136","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient","volume":"16","author":"Cheeley","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib137","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","article-title":"Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association","volume":"17","author":"Warden","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"25","key":"10.1016\/j.jacl.2026.01.011_bib138","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib139","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2025.20620","article-title":"Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial","volume":"335","author":"Ballantyne","year":"2026","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.01.011_bib141","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2023-12-3","article-title":"Inclisiran for the treatment of hypercholesterolaemia","volume":"13","author":"Marrs","year":"2024","journal-title":"Drugs Context"},{"key":"10.1016\/j.jacl.2026.01.011_bib142","unstructured":"Lerodalcibep prescribing information. Accessed January 4, 2026.\u00a0https:\/\/www.lerochol.com\/."},{"issue":"40","key":"10.1016\/j.jacl.2026.01.011_bib143","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","article-title":"Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial","volume":"44","author":"Raal","year":"2023","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.011_bib144","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S2213-8587(24)00313-9","article-title":"Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial","volume":"13","author":"Raal","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib145","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/j.jacl.2023.12.005","article-title":"Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials","volume":"18","author":"Duell","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib146","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jacl.2025.10.065","article-title":"Real-world evaluation of bempedoic acid use in patients with homozygous familial hypercholesterolemia","volume":"20","author":"Warden","year":"2026","journal-title":"J Clin Lipidol"},{"issue":"15","key":"10.1016\/j.jacl.2026.01.011_bib147","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib148","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2021.11.013","article-title":"Real-world utilization of bempedoic acid in an academic preventive cardiology practice","volume":"16","author":"Warden","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"9","key":"10.1016\/j.jacl.2026.01.011_bib149","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0002-9149(94)90579-7","article-title":"The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST)","volume":"74","author":"Walldius","year":"1994","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib150","doi-asserted-by":"crossref","first-page":"292","DOI":"10.5551\/jat.E610","article-title":"Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan","volume":"15","author":"Yamashita","year":"2008","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib151","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5551\/jat.55327","article-title":"Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE)","volume":"28","author":"Yamashita","year":"2021","journal-title":"J Atheroscler Thromb"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib152","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","article-title":"Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial","volume":"149","author":"Raal","year":"2024","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.011_bib153","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/ATVBAHA.117.310217","article-title":"Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor): implications for the efficacy of evolocumab","volume":"38","author":"Thedrez","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9860","key":"10.1016\/j.jacl.2026.01.011_bib154","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.011_bib155","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","article-title":"Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia","volume":"136","author":"Blom","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib156","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","article-title":"Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study","volume":"29","author":"D'Erasmo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib157","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/liv.15497","article-title":"Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia","volume":"43","author":"Larrey","year":"2023","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib158","first-page":"775","article-title":"Long-term experience with lomitapide treatment in patients with homozygous familial hypercholesterolemia: over 10 years of efficacy and safety data","volume":"19","author":"Arca","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.01.011_bib159","unstructured":"The JUXTAPID\u00ae Risk Evaluation and Mitigation Strategy (REMS).\u00a0Accessed January 4, 2026.\u00a0https:\/\/www.juxtapid.com\/rems\/."},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib160","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s12325-021-02031-y","article-title":"A case series assessing the effects of lomitapide on carotid intima-media thickness in adult patients with homozygous familial hypercholesterolaemia in a real-world setting","volume":"39","author":"Blom","year":"2022","journal-title":"Adv Ther"},{"issue":"12","key":"10.1016\/j.jacl.2026.01.011_bib161","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(24)00233-X","article-title":"Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study","volume":"12","author":"Masana","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.jacl.2026.01.011_bib162","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jacl.2026.01.011_bib163","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1161\/ATVBAHA.124.322364","article-title":"Real-world effectiveness and safety of evinacumab in children and adults with homozygous familial hypercholesterolemia: a multisite US perspective-brief report","volume":"45","author":"Wilkinson","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib164","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","article-title":"Evinacumab for pediatric patients with homozygous familial hypercholesterolemia","volume":"149","author":"Wiegman","year":"2024","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jacl.2026.01.011_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100648","article-title":"The long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia","volume":"2","author":"Raal","year":"2023","journal-title":"JACC Adv"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.011_bib166","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jacl.2025.02.012","article-title":"Safety and effectiveness of evinacumab in an infant with homozygous familial hypercholesterolemia: a new renaissance for the very young?","volume":"19","author":"Fornari","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib167","first-page":"410","article-title":"Evinacumab as an adjunct to lipid apheresis in an infant with homozygous familial hypercholesterolemia","volume":"38","author":"Stirnkorb","year":"2025","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.jacl.2026.01.011_bib168","unstructured":"European Commission (EC) extends the approval of Evkeeza\u00ae (evinacumab) to children as young as 6-months old with homozygous familial hypercholesterolemia (HoFH). BioSpace;\u00a02025. https:\/\/www.biospace.com\/press-releases\/european-commission-ec-extends-the-approval-of-evkeeza-evinacumab-to-children-as-young-as-6-months-old-with-homozygous-familial-hypercholesterolemia-hofh. Accessed Feb 13, 2026."},{"key":"10.1016\/j.jacl.2026.01.011_bib169","unstructured":"Regeneron Pharmaceuticals. Evkeeza\u00ae (evinacumab-dgnb) ANGPTL3 antibody approved in the U.S. for children as young as 1 year old with ultra-rare form of high cholesterol; September 2025. Accessed January 6, 2026. https:\/\/www.evkeeza.com\/s\/."},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib170","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1161\/ATVBAHA.123.320609","article-title":"Evinacumab and cardiovascular outcome in patients with homozygous familial hypercholesterolemia","volume":"44","author":"B\u00e9liard","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib171","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jacl.2013.11.002","article-title":"Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy","volume":"8","author":"Vishwanath","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.jacl.2026.01.011_bib172","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.011_bib173","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12265-011-9311-1","article-title":"Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively","volume":"5","author":"Ibrahim","year":"2012","journal-title":"J Cardiovasc Transl Res"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib174","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5551\/jat.RV17029","article-title":"Liver transplantation for homozygous familial hypercholesterolemia","volume":"26","author":"Ishigaki","year":"2019","journal-title":"J Atheroscler Thromb"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib175","doi-asserted-by":"crossref","first-page":"e1055","DOI":"10.1016\/j.jacl.2024.08.008","article-title":"The therapeutic effect of liver transplantation in 14 children with homozygous familial hypercholesterolemia: a prospective cohort: Liver transplant for familial hypercholesterolemia","volume":"18","author":"Lin","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.01.011_bib176","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1454638","article-title":"The effectiveness of liver transplantation in reducing lipid levels in Saudi children with homozygous familial hypercholesterolemia","volume":"11","author":"Al-Ashwal","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib177","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.amjcard.2016.05.042","article-title":"Effects of liver transplantation on lipids and cardiovascular disease in children with homozygous familial hypercholesterolemia","volume":"118","author":"Martinez","year":"2016","journal-title":"Am J Cardiol"},{"issue":"307-308","key":"10.1016\/j.jacl.2026.01.011_bib178","first-page":"807","article-title":"Normal levels of lipoproteins including lipoprotein(a) after liver-heart transplantation in a patient with homozygous familial hypercholesterolaemia","volume":"85","author":"Barbir","year":"1992","journal-title":"Q J Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib179","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13605","article-title":"Society of pediatric liver transplantation: current registry status 2011-2018","volume":"24","author":"Elisofon","year":"2020","journal-title":"Pediatr Transplant"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.011_bib180","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/hep.32223","article-title":"European Liver Transplant Registry: donor and transplant surgery aspects of 16,641 liver transplantations in children","volume":"75","author":"de Ville de Goyet","year":"2022","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib181","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jacl.2019.09.007","article-title":"Coronary artery disease in a child with homozygous familial hypercholesterolemia: regression after liver transplantation","volume":"13","author":"Cephus","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.01.011_bib182","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.567895","article-title":"Case report: liver transplantation in homozygous familial hypercholesterolemia (HoFH)-long-term follow-up of a patient and literature review","volume":"8","author":"Mlinaric","year":"2020","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib183","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2015.01.007","article-title":"Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia","volume":"239","author":"Lefort","year":"2015","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib184","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-0740","article-title":"Progressive aortic stenosis in homozygous familial hypercholesterolemia after liver transplant","volume":"138","author":"Greco","year":"2016","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.jacl.2026.01.011_bib185","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.01.011_bib186","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2021.09.003","article-title":"Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia","volume":"335","author":"Klevmoen","year":"2021","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib187","doi-asserted-by":"crossref","first-page":"e664","DOI":"10.1016\/j.jacl.2024.05.005","article-title":"Dyslipidemia management in women of reproductive potential: an Expert Clinical Consensus from the National Lipid Association","volume":"18","author":"Agarwala","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.jacl.2026.01.011_bib188","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jacl.2016.07.002","article-title":"The risks of statin use in pregnancy: a systematic review","volume":"10","author":"Karalis","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.01.011_bib189","unstructured":"U.S. Food & Drug Administration. FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins; 2021."},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib190","doi-asserted-by":"crossref","first-page":"720.e1","DOI":"10.1016\/j.ajog.2015.12.038","article-title":"Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial","volume":"214","author":"Costantine","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.jacl.2026.01.011_bib191","doi-asserted-by":"crossref","first-page":"666.e1","DOI":"10.1016\/j.ajog.2021.05.018","article-title":"A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia","volume":"225","author":"Costantine","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jacl.2026.01.011_bib192","article-title":"Pravastatin in preeclampsia: a meta-analysis and systematic review","volume":"9","author":"M\u00e9sz\u00e1ros","year":"2022","journal-title":"Front Med"},{"issue":"9","key":"10.1016\/j.jacl.2026.01.011_bib193","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/CIRCULATIONAHA.121.053963","article-title":"Pravastatin versus placebo in pregnancies at high risk of term preeclampsia","volume":"144","author":"D\u00f6bert","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.01.011_bib194","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.atherosclerosissup.2015.02.024","article-title":"Pregnancy in homozygous familial hypercholesterolemia\u2014importance of LDL-apheresis","volume":"18","author":"Blaha","year":"2015","journal-title":"Atheroscler Suppl"},{"issue":"7","key":"10.1016\/j.jacl.2026.01.011_bib195","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003294","article-title":"Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia","volume":"5","author":"Wang","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"suppl 3","key":"10.1016\/j.jacl.2026.01.011_bib196","first-page":"59","article-title":"Maternal lipid metabolism and placental lipid transfer","volume":"65","author":"Herrera","year":"2006","journal-title":"Horm Res"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib197","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.atherosclerosis.2006.01.002","article-title":"Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia","volume":"189","author":"Amundsen","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.01.011_bib198","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2017.10.006","article-title":"Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH\u2122 patient registry","volume":"267","author":"Amrock","year":"2017","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib199","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jacl.2022.11.009","article-title":"Sex-related differences in premature cardiovascular disease in familial hypercholesterolemia","volume":"17","author":"Agarwala","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib200","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41598-023-27963-z","article-title":"Women with familial hypercholesterolemia phenotype are undertreated and poorly controlled compared to men","volume":"13","author":"Zamora","year":"2023","journal-title":"Sci Rep"},{"issue":"17","key":"10.1016\/j.jacl.2026.01.011_bib201","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.020890","article-title":"Racial disparities in modifiable risk factors and statin usage in black patients with familial hypercholesterolemia","volume":"10","author":"Agarwala","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib202","first-page":"1020","article-title":"Using healthcare claims data to identify health disparities for individuals with familial hypercholesterolemia","volume":"19","author":"McGowan","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2026.01.011_bib203","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamacardio.2019.5173","article-title":"Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action","volume":"5","author":"Wilemon","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.jacl.2026.01.011_bib204","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40273-014-0132-3","article-title":"How to estimate productivity costs in economic evaluations","volume":"32","author":"Krol","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.jacl.2026.01.011_bib205","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/CIR.0b013e3182285a81","article-title":"Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association","volume":"124","author":"Weintraub","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacl.2026.01.011_bib206","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacl.2023.11.001","article-title":"A systematic review of cost-effectiveness analysis of different screening strategies for familial hypercholesterolemia","volume":"18","author":"Meng","year":"2024","journal-title":"J Clin Lipidol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:02:50Z","timestamp":1776427370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426000103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":206,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1933287426000103"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.01.011","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}